Our findings demonstrate that the pharmacological co-inhibition of PLK1 and ACLY significantly suppresses pan-cancer cell proliferation compared to single-agent treatment and that this combination downregulated UBE2C mRNA and protein expression, which revealed a novel potential molecular mechanism. Here, ACLY is linked to cancer.